Gypenoside LI

Gypenoside LI, a gypenoside monomer, possesses anti-tumor activity. Gypenoside LI induces cell apoptosis, cell cycle and migration.

Product information

CAS Number: 94987-10-7

Molecular Weight: 801.01

Formula: C42H72O14

Chemical Name: (2S,3R,4S,5S,6R)-2-{[(2R,3R,4S,5S,6R)-2-{[(1S,3aR,3bR,5aR,7R,8R,9aR,9bR,11R,11aR)-8,11-dihydroxy-1-[(2R)-2-hydroxy-6-methylhept-5-en-2-yl]-3a,3b,6,6,9a-pentamethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-7-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

Smiles: CC1(C)[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)C[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C[C@@H](O)[C@@H]2[C@H](CC[C@@]12C)[C@](C)(O)CCC=C(C)C

InChiKey: LTJZMSTVPKBWKB-XUYZQZLKSA-N

InChi: InChI=1S/C42H72O14/c1-20(2)10-9-13-42(8,52)21-11-14-41(7)28(21)22(45)16-27-39(5)17-23(46)35(38(3,4)26(39)12-15-40(27,41)6)56-37-34(32(50)30(48)25(19-44)54-37)55-36-33(51)31(49)29(47)24(18-43)53-36/h10,21-37,43-52H,9,11-19H2,1-8H3/t21-,22+,23+,24+,25+,26-,27+,28-,29+,30+,31-,32-,33+,34+,35-,36-,37-,39-,40+,41+,42+/m0/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Gypenoside LI (0-80 μM) inhibits A549 cells in a dose-dependent manner. Gypenoside LI induces G2/M and arrest apoptosis in A549 cells. Gypenoside LI increases intracellular ROS level. Gypenoside LI suppressed migration of A549 cells. Gypenoside LI could obviously suppress the expression of CDK1 protein rather than CDK2 and CDK4 proteins. Gypenoside LI inhibits cell proliferation and upregulates expression of miR-128-3p in melanoma cells. Gypenoside LI (75 and 29.71 μg/mL) can induce intrinsic apoptosis along with S phase arrest. Gypenoside LI inhibited the colony formation ability of melanoma through inhibition of the Wnt/β-catenin signaling pathway. Gypenoside LI induces PARP cleavage, increased the expression of cleaved caspase-9 and BID death agonist, and downregulates the expression of FLIP (long form) and BCl-2 in the A375 and SK-MEL-28 melanoma cells.

Products are for research use only. Not for human use.